Cambridge University biotech spin-out Definigen has secured £1.3m ($2.13m) in series A funding in a round led by the university’s tech transfer unit Cambridge Enterprise, and joined by early-stage investor 24Haymarket and Cambridge-based biotech Abcam’s co-founder Jonathan Milner.

Cambridge Enterprise’s involvement marks the largest investment made by the university through its seed funds in a single round to date, weighing in at £525,000.

Founded in April last year, Definigen is commercialising stem cell technology developed at Cambridge, and is one…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?